Recent work by Poplawska et al. (2024) emphasizes the lack of ethnic diversity in clinical trials involving COMT inhibitors, underscoring the importance of our study in addressing the inclusion of underrepresented populations in research on COMT variants and PD risk [23]. Here, COMT is linked to Parkinson disease.